Advertisement

Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

  • James C. Sisson
  • Anca M. Avram
  • Domenico Rubello
  • Milton D. Gross
Letter to the Editor

Dear Sir,

All agree that radioiodine therapy will remove hyperthyroidism caused by Graves’ and toxic nodular diseases. However, therapeutic dosing of radioioidine remains controversial. Recent reports have promulgated the virtues of prescribing fixed doses of 131I [1, 2, 3]. Others have delineated the value of calculating doses based on thyroid volume and fractional concentration of the radionuclide [4, 5, 6].

Among those prescribing radioiodine therapies, there has been agreement on two principles. First, following elimination of hyperthyroidism, hypothyroidism is an almost inevitable consequence of radioiodine treatment [7]. Thus, few, if any, therapists now seek to produce euthyroidism. Second, hyperthyroidism impairs health, creates disability, and, occasionally, poses a risk to life; the disorder should be eliminated as soon as possible. A third principle has frequently been neglected in the arguments for one or the other method of therapy: radiation to the patients can have...

Keywords

Hyperthyroidism Intelligent Design Propylthiouracil Thyroid Volume Antithyroid Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radiodiodine treatment of hyperthyroidism—prognostic factors for outcome. J Clin Endocrinol Metab 2001;86:3611–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab 2003;88:978–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Saimi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol 2004;61:641–8.CrossRefGoogle Scholar
  4. 4.
    Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves’ hyperthyroidism with radioioidine; results of a prospective study. Thyroid 1997;2:247–51.Google Scholar
  5. 5.
    Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy of Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002;29:1118–24.CrossRefGoogle Scholar
  6. 6.
    Alexander EK, Larsen PR. High dose 131I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2002;87:1073–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Brit Med J 1984;289:361–3.Google Scholar
  8. 8.
    IRCP. Protection of the patient in medicine. IRCP publication 52. Ann IRCP 1987;17 4:5. New York: Pergamon Press.Google Scholar
  9. 9.
    Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998;280:347–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Pollycove M, Feinendegen LE. Biologic responses to low doses of ionizing radiation: detrement versus hormesis. Part 2. Dose responses in organisms. J Nucl Med 2001;42:26N–37N.PubMedGoogle Scholar
  11. 11.
    IRCP. Radiation dose to patients from radiopharmaceuticals. ICRP publication 53. Ann IRCP 1994;278. New York: Pergamon Press.Google Scholar
  12. 12.
    Willemsen UF, Knewewitsch P, Kreisig T, Pickardt CR, Kirsch CM. Functional results of radioiodine therapy with 300-Gy absorbed dose in Graves’ disease. Eur J Nucl Med 1993;20:1051–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, et al. Calculation of the radioiodine dose for the treatment of Graves’ hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid 1999;9:865–9.PubMedGoogle Scholar
  14. 14.
    Lucas KJ. Use of ultrasound volume in calculating radioactive iodine dose in hyperthyroidism. Thyroid 2000;10:151–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995;25:186–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • James C. Sisson
    • 1
  • Anca M. Avram
    • 1
  • Domenico Rubello
    • 2
  • Milton D. Gross
    • 1
  1. 1.Division of Nuclear Medicine, Department of RadiologyUniversity of Michigan and Department of Veterans Affairs Health SystemsAnn ArborUSA
  2. 2.Nuclear Medicine ServiceS. Maria della Misercordia HospitalRovigoItaly

Personalised recommendations